J

Johnson & Johnson

Makes prescription drugs and medical devices

General Sales Manager - VELYS

Full-TimeDeadline 10/29/26
No salary listed
Senior, Expert
Bachelor's
Gurugram, Haryana, India
In Person
Sales & Account ManagementField Sales

About the job

Requirements
  • A post-graduation degree or diploma in Business Management, preferably from a premier business school.
  • Eight to ten years of proven sales experience.
  • MedTech experience is mandatory, preferably in Orthopaedics.
Responsibilities
  • Drive the business for the VELYS franchise across the North and East region in line with company policies, goals, and franchise direction.
  • Develop new businesses, expand into new territories, and establish a new dealer network.
  • Develop and implement sales strategies and objectives.
  • Maintain in-depth knowledge of capital equipment, consumables, other company products and services, customer needs, and market trends.
  • Lead, direct, motivate, coach, and develop the sales team to achieve or exceed sales targets.
  • Develop long-term customer relationships to increase satisfaction, loyalty, and confidence in the company as a preferred supplier.
  • Deliver the assigned regional business plan and achieve monthly, quarterly, and annual targets.
  • Set strategies and plans to expand the market and realize market potential.
  • Lead senior-level negotiations and optimize contractual opportunities for long-term supply arrangements.
  • Analyze sales reports, reprioritize resources, and maximize sales opportunities.
  • Establish monitoring systems for sales-plan volume, price, and value objectives.
  • Identify and direct action on tender opportunities through cooperation with appropriate departments.
  • Meet accounts-receivable and days-sales-outstanding targets and manage receivables according to company policy.
  • Meet installation targets for VELYS and other digital surgery products.
  • Increase utilization of existing VELYS accounts and ensure PPU accounts meet targets.
  • Upgrade existing accounts with Uni and VHN.
  • Create a lead-generation process and maintain a healthy sales funnel.
  • Translate current and future customer needs into sales opportunities.
  • Advise on new-account expansion and account conversion.
  • Work in the field with supervisors to cover key accounts and maintain customer rapport.
  • Analyze the competitive market environment, including competitors’ structures, cultures, manpower, distribution, capabilities, weaknesses, and customer preferences.
  • Develop sales plans for supervisors with account, product-group, and monthly, quarterly, and annual objectives.
  • Coach the direct team on territory coverage, customer-call plans, and key-account strategies and growth plans.
  • Conduct regular account-team reviews to improve short- and long-term strategies and action plans.
  • Use expert sales-process and specialist-selling skills, teach those skills to others, and improve the selling process.
  • Sell in surgery to remain current on customer needs and market trends.
  • Use knowledge of internal organizational resources, priorities, and needs to achieve the sales plan.
  • Develop and maintain customer relationships, obtain feedback, supervise customer perceptions, and use feedback to improve customer satisfaction.
  • Develop and implement strategies to increase customer satisfaction, confidence, and loyalty.
  • Design customer-support services and tender arrangements, including electronic initiatives and use of company services.
  • Ensure customer complaints are handled promptly and professionally in compliance with the customer complaints procedure.
  • Lead internal relationships and processes and access internal specialists, information, and support as needed.
  • Align with franchise marketing groups to optimize sales results.
  • Use supply-chain processes and health economics principles to identify service-innovation opportunities.
  • Provide information to marketing and support departments to improve internal processes, decision-making, and actions.
  • Prepare and submit the territory budget and supervise team compliance with selling and marketing expenses.
  • Manage operating expenses, including transportation, advertising and promotion, entertainment, and travel, while maintaining productivity.
  • Manage the use of resources and equipment.
  • Plan sample and expense utilization within budget, guidelines, and regulatory requirements.
  • Supervise customer creditworthiness and accounts receivable to achieve objectives.
  • Supervise inventory levels to meet objectives and maintain adequate major product-category inventory.
  • Develop and implement a distribution network for the assigned territory.
  • Ensure the team has an appropriate mix of skills and abilities.
  • Maintain an appropriate succession plan.
  • Develop teamwork and cooperation within the team and with other functions.
  • Develop employees’ confidence and empowerment in resolving customer issues.
  • Interview and hire employees using targeted selection methods.
  • Ensure compliance with performance-management processes and conduct semiannual performance evaluations of supervisors.
  • Identify improvement areas and create individual development plans and development actions for team members.
  • Conduct Credo feedback, identify issues and action plans, and ensure completion of agreed plans.
  • Disseminate and clarify company information and review business status with the team.
  • Drive capabilities including capital selling, digital solutions, and technology adoption.
  • Communicate individual Credo responsibilities to the sales team.
  • Manage the business according to Credo ethics and values while pursuing business outcomes.
  • Maintain customer relationships according to high ethical standards.
Desired Qualifications
  • Business Development
  • Customer Centricity
  • Developing Others
  • Healthcare Trends
  • Inclusive Leadership
  • Interpersonal Influence
  • Leadership
  • Market Knowledge
  • Objectives and Key Results
  • Presentation Design
  • Process Improvements
  • Revenue Management
  • Sales
  • Solutions Selling
  • Strategic Sales Planning
  • Sustainable Procurement
  • Technical Credibility
  • Vendor Selection
  • Orthopaedics experience

About the company

Johnson & Johnson develops prescription medicines and makes medical devices for hospitals, and unlike most big drugmakers, it runs both businesses under one roof. In 2015, its Darzalex became the first antibody drug approved for multiple myeloma, a blood cancer. Its medicines treat cancer, immune diseases such as psoriasis, and mental illnesses such as depression, and patented drugs bring in most of its sales. Its MedTech unit makes heart pumps, catheters that treat irregular heartbeats, surgical sutures, and Acuvue contact lenses. It was founded in 1886 to make sterile surgical dressings, is based in New Brunswick, New Jersey, and spun off its consumer brands, such as Tylenol and Band-Aid, as Kenvue in 2023.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Cancer drugs drive growth: oncology sales rose 17% to $7.4 billion in the June 2026 quarter, 29% of the total.
  • Stock grants have gained value: J&J shares rose 58% in the year to September 2026, versus 23% for Pfizer.
  • Students have a way in: J&J listed 1,897 open jobs in October 2026, including 201 internships, co-ops and early-career roles.

What critics are saying

  • Its key immune drug trails: AbbVie's Skyrizi outsold Tremfya $5.5 billion to $2.0 billion in the June 2026 quarter.
  • Orthopedics is leaving J&J: in September 2026, it was negotiating a $20 billion sale to buyout firm Apollo.
  • Baby powder suits remain costly: in July 2026, J&J agreed to pay $5.5 billion to end about 76,000 cancer claims.

What makes Johnson & Johnson unique

  • Its debt is rated safer than America's: S&P's top AAA rating goes to only two US companies, J&J and Microsoft.
  • Employees rank above shareholders: J&J's 1943 Credo lists duties to patients, then staff and communities, with stockholders last.
  • Its psoriasis pill is a first: Icotyde, approved March 2026, blocks an immune signal rivals target only by injection.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Dental Insurance
  • Vision Insurance
  • Life Insurance
  • Disability Insurance
  • 401(k) Retirement Plan
  • 401(k) Company Match
  • Paid Vacation
  • Paid Sick Leave
  • Paid Holidays
  • Remote Work Options
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-2%

1 year growth

-2%

2 year growth

-2%
Yahoo Finance
Oct 20th, 2026
Johnson & Johnson and Amgen beat the market in 2026, but can the dividend stocks keep going?

Johnson & Johnson and Amgen, two dividend stocks that have beaten the broader market this year, could suit investors bracing for a possible crash. J&J's latest quarter beat expectations, and it slightly raised its 2026 guidance. But its medtech unit is struggling, as demand for the Impella heart pump has fallen amid safety questions and a US Class 1 recall. Long-term, it has new drugs, a robotic surgery system approved in the US, and a proposed $5.5 billion talc settlement. It is a Dividend King with 64 straight years of payout increases. Amgen's second-quarter revenue rose 10% to $10.1 billion, despite pressure on Tavneos and falling denosumab sales. It has raised payouts 152% over a decade and offers a 2.3% forward yield, against 1.1% for the S&P 500.

Yahoo Finance
Oct 17th, 2026
Johnson & Johnson dips after $25.4B quarter: buy the Dividend King?

Johnson & Johnson shares fell after the healthcare group reported third-quarter results, despite a beat-and-raise quarter. Revenue rose 5.9% to $25.4 billion, while adjusted earnings per share fell 7.5% to $2.59, a drop attributed mostly to acquisitions. Innovative medicine sales rose 7.7% to $16.8 billion, led by cancer drug Darzalex ($4.2 billion) and Tremfya ($2.4 billion, up 68.3%). The company raised its 2026 operational sales guidance to $100.7 billion at the midpoint, from $100.6 billion. Medtech revenue grew just 2.5% to $8.6 billion, which drove the share dip. Safety and efficacy concerns over its Impella heart pumps hurt the cardiovascular unit abroad. The company has raised its dividend for 64 consecutive years, making it a Dividend King.

Yahoo Finance
Oct 14th, 2026
J&J shares fall 6% as MedTech sales miss forecasts despite $25.4B revenue beat

Johnson & Johnson shares fell 6% after its medical device sales missed forecasts, even though third-quarter results beat estimates. Revenue was $25.4 billion, above the $25.37 billion expected. Adjusted earnings were $2.59 per share, $0.07 above estimates. MedTech sales rose 2.5% to $8.6 billion, below the $8.71 billion forecast, and marked a second straight quarterly miss. The company blamed the Middle East conflict, European austerity, and pricing pressure in China. Pharmaceutical sales rose 7.7% to $16.76 billion. Net earnings fell to $210 million from $2.12 a year earlier, hit by about $7 billion in talc settlement and deal costs. The company raised its full-year sales outlook to about $101.2 billion and said it is leaning toward spinning off its orthopedics unit, DePuy Synthes, by mid-2027.

Yahoo Finance
Oct 13th, 2026
J&J medtech sales rise just 2.5% to $8.64B as Abiomed slump weighs on cardiovascular

Johnson & Johnson's medtech sales rose 2.5% year over year to $8.64 billion in the third quarter, missing internal expectations. Growth has slowed for two quarters in a row, after rising more than 7% in the first quarter and last year's fourth quarter. The cardiovascular unit grew 4.3% to $2.31 billion. Its Abiomed business, bought in 2022 for $16.6 billion, fell 2.3% to $412 million. Tim Schmid, worldwide chairman of medtech, blamed lower patient volume after an unfavourable UK study of the Impella heart device. He called the setback temporary and said pressure also came from sales outside the US. J&J expects results from its PROTECT IV study of nearly 1,300 patients next year.

Yahoo Finance
Oct 13th, 2026
Memory stocks slide on Chinese chip breakthrough as UnitedHealth and Goldman beat estimates

US stock futures were mixed on Tuesday as investors weighed a wave of earnings reports. Dow futures rose 0.9%, S&P 500 futures slipped 0.1%, and Nasdaq futures fell 0.7%. Memory stocks fell for a second day after a Chinese chipmaker, CXMT, said it had made a breakthrough in memory chip production. Roundhill Memory ETF fell more than 5% in premarket trading. UnitedHealth rose more than 2% after it earned an adjusted $4.69 per share on $112.69 billion in revenue, beating estimates. It raised its full-year earnings outlook to at least $20.50 per share. Goldman Sachs gained more than 3% on strong results. JPMorgan Chase, Wells Fargo, and Citigroup fell short in parts of their reports. Johnson & Johnson fell 2% after $25.40 billion in sales narrowly missed estimates, though it raised its full-year forecasts.